NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
CytomX Therapeutics, Inc. CTMX
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$76.2M
▼ 44.8% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-35.2%
Net margin · FY25
-22.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 76.2M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 23 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-35.2%
Return on equity, FY2025
ROE
Operating margin-29.3%
Net margin-22.8%
Return on assets-12.8%
Each USD of equity lost 35 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+2.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+12.8%
+2.2%
+25.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.17B
Shares outstanding, FY2025
Change, 5 years+76.0%
Change, 10 years—
The share count grew 76% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 151.6M
total assets, end of FY2025
Total assetsUSD 151.6M
EquityUSD 99.0M
CashUSD 12.7M
Current ratio3.09×
Equity funds 65% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.1
0.0
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.0
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
−1.16
−1.63
−4.90
−35.25
−24.46
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−35.2
·
·
·
·
−732.6
−164.7
−82.3
−58.1
−57.6
−148.9
·
·
Shares out B
0.17
0.08
0.07
0.07
0.07
0.05
0.05
0.05
0.04
0.04
0.04
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
29 of 29
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed